pyrazines has been researched along with Shingles in 21 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 10 (47.62) | 29.6817 |
2010's | 10 (47.62) | 24.3611 |
2020's | 1 (4.76) | 2.80 |
Authors | Studies |
---|---|
Feng, YF; Li, G; Sun, YQ; Wei, XF; Yang, WH; Zhang, QK | 1 |
Hata, T; Li, C; Two, AM | 1 |
Fujihara, S; Imataki, O; Kirizume, K; Ohnishi, H; Ohue, Y; Shintani, T; Waki, F | 1 |
Anderson, KC; Ben-Yehuda, D; Chanan-Khan, A; Facon, T; Goldschmidt, H; Harousseau, JL; Lonial, S; Neuwirth, R; Reece, D; Richardson, PG; Schuster, MW; Sonneveld, P; Stadtmauer, EA | 1 |
Do, YR; Joo, YD; Kim, BS; Kim, H; Kim, HJ; Kim, I; Kim, K; Kim, SJ; Kwon, JH; Lee, HJ; Lee, JH; Lee, NR; Lee, WS; Nam, SH; Shin, HJ; Sohn, SK; Suh, C; Won, JH; Yoon, SS | 1 |
Allen, S; Mehta, J; Singhal, S; Vickrey, E | 1 |
Adam, Z; Buchler, T; Buresova, L; Hajek, R; Krejci, M; Krivanova, A; Pour, L; Sandecka, V; Vorlicek, J; Zahradova, L | 1 |
Birner, A; Boral, A; Diener, JG; Esseltine, DL; Ghobrial, IM; Ioakimidis, L; Keogh, GP; Matous, J; Mattern, J; Myers, TJ; Nelson, M; Patterson, CJ; Sheehy, P; Soumerai, JD; Treon, SP; Willen, M | 1 |
Chou, T; Hasegawa, Y; Hirose, T; Imai, Y; Ishiguro, T; Kawahara, F; Nagai, H | 1 |
Alexandrescu, DT; Dasanu, CA | 1 |
Heider, U; Kaiser, M; Kleeberg, L; Rademacher, J; Sezer, O; von Metzler, I | 1 |
Bae, SH; Do, YR; Kim, K; Kim, SJ; Lee, JJ; Yang, DH | 1 |
Aoki, T; Imahashi, N; Kitamura, K; Nishiyama, T | 1 |
Guo, H; Mao, J; Qian, X; Sun, C; Sun, H | 1 |
Bergamo, S; di Meo, N; Dondas, A; Trevisan, G | 1 |
Bacovsky, J; Langova, K; Minarik, J; Pika, T; Scudla, V | 1 |
Fujita, Y; Fukushima, T; Iwao, H; Kawanami, T; Masaki, Y; Miki, M; Motoo, Y; Nakajima, A; Nakajima, H; Nakamura, T; Okazaki, T; Sakai, T; Sato, T; Sawaki, T; Tanaka, M; Umehara, H | 1 |
Bernstein, SH; de Vos, S; Esseltine, DL; Fisher, RI; Goy, A; Morrison, VA; Neuwirth, R; Solh, M | 1 |
Lokhorst, HM; Sonneveld, P; van Wieringen, W; Vellenga, E; Wu, KL; Zweegman, S | 1 |
Atanackovic, D; Ayuk, F; Kröger, N; Renges, H; Schieder, H; Zabelina, T; Zander, A | 1 |
Borroni, G; Corso, A; Lazzarino, M; Mangiacavalli, S; Rosso, R; Varettoni, M; Vassallo, C; Zappasodi, P | 1 |
4 trial(s) available for pyrazines and Shingles
Article | Year |
---|---|
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Herpes Zoster; Humans; Multiple Myeloma; Pyrazines; Recurrence; Virus Activation | 2008 |
Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Blood Viscosity; Bone Marrow Neoplasms; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Hematocrit; Herpes Zoster; Humans; Immunoglobulin M; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Count; Pyrazines; Rituximab; Treatment Outcome; Waldenstrom Macroglobulinemia | 2009 |
Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Herpes Zoster; Humans; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Time Factors; Treatment Outcome | 2005 |
Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; CD3 Complex; Chronic Disease; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Herpes Zoster; Humans; Leukopenia; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Remission Induction; Stem Cell Transplantation; Thrombocytopenia; Transplantation, Homologous | 2006 |
17 other study(ies) available for pyrazines and Shingles
Article | Year |
---|---|
[Analysis of Risk Factors of Herpes Zoster in Patients with Multiple Myeloma Treated with Bortezomib].
Topics: Boronic Acids; Bortezomib; Herpes Zoster; Humans; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk Factors | 2020 |
A case of eosinophilic dermatosis of hematologic malignancy in a patient with multiple myeloma.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Eosinophilia; Herpes Simplex; Herpes Zoster; Humans; Insect Bites and Stings; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Paraneoplastic Syndromes; Pemphigoid, Bullous; Pyrazines; Skin Diseases | 2014 |
[Aggravated post-herpetic neuralgia due to bortezomib].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Herpes Zoster; Humans; Male; Middle Aged; Multiple Myeloma; Neuralgia, Postherpetic; Protease Inhibitors; Pyrazines; Recurrence | 2008 |
Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Herpes Zoster; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies | 2008 |
Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy.
Topics: Acyclovir; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Herpes Zoster; Herpesvirus 3, Human; Humans; Multiple Myeloma; Pyrazines; Retrospective Studies; Virus Activation | 2009 |
Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib.
Topics: Acyclovir; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Virus Activation | 2009 |
[Prophylaxis with acyclovir for herpes zoster infection during bortezomib-dexamethasone combination therapy].
Topics: Acyclovir; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Herpes Zoster; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Retrospective Studies | 2009 |
Prophylactic antivirals may be helpful in prevention of varicella-zoster virus reactivation in myeloma, but are they safe?
Topics: Acyclovir; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Drug Monitoring; Herpes Zoster; Herpesvirus 3, Human; Humans; Incidence; Multiple Myeloma; Neurotoxicity Syndromes; Pyrazines; Renal Insufficiency; Virus Activation | 2010 |
Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib.
Topics: Acyclovir; Boronic Acids; Bortezomib; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Multiple Myeloma; Pyrazines; T-Lymphocytes | 2010 |
Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study.
Topics: Acyclovir; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
Efficacy of continuous, daily, oral, ultra-low-dose 200 mg acyclovir to prevent herpes zoster events among bortezomib-treated patients: a report from retrospective study.
Topics: Acyclovir; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk Factors; Secondary Prevention; Treatment Outcome | 2011 |
Varicella-zoster virus prophylaxis with the traditional Chinese medicine Radix isatidis (Banlangen) in patients with multiple myeloma treated with bortezomib.
Topics: Adult; Aged; Antibiotic Prophylaxis; Boronic Acids; Bortezomib; Drugs, Chinese Herbal; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Isatis; Male; Middle Aged; Multiple Myeloma; Phytotherapy; Plant Roots; Pyrazines | 2011 |
Bortezomib and bilateral herpes zoster.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Fatal Outcome; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Multiple Myeloma; Pyrazines; Virus Activation | 2012 |
Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients.
Topics: Acyclovir; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Herpes Zoster; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies | 2012 |
Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib.
Topics: Acyclovir; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Valacyclovir; Valine; Virus Activation | 2012 |
Herpes zoster complicating bortezomib therapy of relapsed/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Herpes Zoster; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Pyrazines; Recurrence; Risk Factors | 2013 |
Late onset of bortezomib-associated cutaneous reaction following herpes zoster.
Topics: Acyclovir; Anti-Inflammatory Agents; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Dexamethasone; Exanthema; Herpes Zoster; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Skin; Treatment Outcome | 2007 |